CJC-1295 + Ipamorelin 10mg
$45.00
CJC-1295 + Ipamorelin blend combines a long-acting GHRH analog (CJC-1295 with DAC) with a selective GH secretagogue (Ipamorelin) to synergistically amplify pulsatile growth hormone release in laboratory research models. Research investigates effects on IGF-1, body composition, and sleep architecture. For in vitro laboratory research use only.
Research & Studies
Research Use Only
For in vitro laboratory research use only. Not for human consumption, medical use, or self-administration. Not evaluated by the FDA. Purchaser confirms they are a qualified researcher and assumes all responsibility for compliance with applicable federal, state, and local laws. This compound may be regulated as a controlled substance or prescription drug in certain jurisdictions.
In Vitro Research Protocol Reference
Research Concentration
300 mcg CJC-1295 (no DAC) + 300 mcg Ipamorelin
Frequency
1–3x daily
Administration
Subcutaneous injection
Synergistic GH-releasing blend. CJC-1295 (Mod GRF 1-29 without DAC) amplifies the GH pulse amplitude while Ipamorelin triggers the pulse via ghrelin receptor agonism. Administer together to mimic natural pulsatile GH release. Reconstitute 10 mg vial with bacteriostatic water. Cycled 4–8 weeks followed by a 2–4 week break. Monitor IGF-1, fasting glucose, and cortisol.
CJC-1295 + Ipamorelin 10mg
$45.00
Frequently Bought Together
Bac Water 10ml
$8.00
Injection Bundle
$5.00
Epithalon 10mg
$35.00